TABLE 1.
List of exomiRs used for cancer diagnosis.
| Centralize the miRNAs ID | Pattern of expression | Cancer type | Tumor stage | Body fluid source | References |
|---|---|---|---|---|---|
| ExomiR-92 | Increased | Colorectal cancer | All stages | Plasma and tissue samples | Ng et al. (2009) |
| ExomiR-17-5p and exomiR-92a-3p | Increased | Colorectal cancer | Higher clinical stages | Serum | Fu et al. (2018) |
| ExomiR-17-5p, exomiR-21, exomiR-106a and exomiR-106b | Increased | Gastric cancer | Stages I-IV | Plasma | Tsujiura et al. (2010) |
| ExomiR-21, exomiR-155, exomiR-210 and exomiR-196a | Increased | Pancreatic adenocarcinoma patients | All stages | Plasma | Wang et al. (2009) |
| ExomiR-500 | Increased | Hepatocellular carcinoma | Not mentioned | Serum | Yamamoto et al. (2009) |
| ExomiR-184 | Increased | Squamous-cell carcinoma of the tongue | Not mentioned | Plasma | Wong et al. (2008) |
| ExomiR-125a and exomiR-200a | Decreased | Oral squamous-cell carcinoma | Stages I-IV | Saliva | Park et al. (2009) |
| 63 exomiRs | Increased | Non-small-cell lung cancer | Stages I-IV | Serum | (Chen et al., 2008a) |
| 34 exomiRs | Increased | Asymptomatic NSCLC | Early-stage nodule (Ia or Ib) | Serum | Bianchi et al. (2011) |
| 21 exomiRs | Increased | Lung cancer | 12–28 before and at the time of diagnosis | Plasma | Boeri et al. (2011) |
| hsa-miR-212, -214, −205, −210, −203, −191, −192, −146, −155, −21, −106a and -17-3p | Increased | Lung adenocarcinoma | Stages I-IV | Tissues biopsy | Rabinowits et al. (2009) |
| ExomiR-200-5p, exomiR-379, exomiR-139-5p and exomiR-378a | Increased | Lung adenocarcinoma | Early-stage nodule (Ia or Ib) | Tissue biopsy and plasma | Cazzoli et al. (2013) |
| ExomiR-141 and other 15 exomiRs | Increased | Prostate cancer | Stage 3 and 4 | Serum | Lodes et al. (2009) |
| ExomiR-21-5p, exomiR-574-3p, and exomiR-141-5p | Increased | Prostate cancer | Not mentioned | Urine | Samsonov et al. (2016) |
| ExomiR-92, exomiR-93 and exomiR-126 | Increased | Epithelial ovarian cancer | Stages I-IV | Serum | Resnick et al. (2009) |
| ExomiR-21, exomiR-141, exomiR-200a, exomiR-200c, exomiR-200b, exomiR-203, exomiR-205 and exomiR-214) | Increased | Ovarian cancer | Various stages | Serum | Taylor and Gercel-Taylor (2008) |
| ExomiR-195 | Increased | Breast cancer | Stage IV | Serum, plasma, or whole blood | Heneghan et al. (2010) |
| ExomiR-101 and exomiR-372 | Increased | Breast cancer and triple-negative breast cancer | pT1 pT2-4 |
Serum | Eichelser et al. (2014) |
| ExomiR-199a-3p | Increased | Pediatric neuroblastoma | Not mentioned | Plasma | Ma et al. (2019) |
| ExomiR-16 | Increased | Pediatric acute lymphoblastic leukemia | Not mentioned | Blood | Kaddar et al. (2009) |
| ExomiR-21 | Increased | Pediatric Hepatoblastoma | Not mentioned | Plasma | Liu et al. (2016b) |
| ExomiR-7112-5p, exomiR-885-3p and exomiR-1245a | Increased | Pediatric acute myeloid leukaemia | Risk of disease recurrence | Plasma | Zampini et al. (2017) |
| ExomiR-25-3p | Increased | Osteosarcoma | Not mentioned | Serum | Fujiwara et al. (2017) |
| ExomiR-125b | Decreased | Ewing’s sarcoma | Metastasis and non-metastasis | Serum | Nie et al. (2015) |
| ExomiR-21 | Increased | Diffuse large B cell lymphoma | Stages I-IV | Serum | Lawrie et al. (2008) |
| ExomiR-92a | Decreased | Acute leukemias | Not mentioned | Plasma | Tanaka et al. (2009) |
| ExomiR-148a, exomiR-181a, exomiR-20a, exomiR-221, exomiR-625, and exomiR-9 | Increased | Multiple myeloma | Not mentioned | Plasma | Huang et al. (2012a) |
| ExomiR-32, exomiR-98 and exomiR-374 | Decreased | Chronic lymphocytic leukemia | Not mentioned | Blood | Rahimi et al. (2021) |
| ExomiR-451 | Increased | Chronic myelogenous leukemia | Chronic stage | Plasma | Keramati et al. (2021) |